Opiant Pharmaceuticals, Inc. News Releases https://ir.opiant.com/ Opiant Pharmaceuticals, Inc. News Releases en Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-reports-first-quarter-2019-financial SANTA MONICA, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the three months ended March 31, 2019 , and provided a Thu, 09 May 2019 16:05:00 -0400 Opiant Pharmaceuticals, Inc. News Releases 8381 Opiant Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, May 9 https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-report-first-quarter-2019-financial SANTA MONICA, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the first quarter ended March 31, Tue, 30 Apr 2019 16:05:00 -0400 Opiant Pharmaceuticals, Inc. News Releases 8366 Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-announces-publication-clinical-0 Data published online in the Journal of Pharmacology and Experimental Therapeutics SANTA MONICA, Calif. , April 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that Mon, 08 Apr 2019 08:00:00 -0400 Opiant Pharmaceuticals, Inc. News Releases 8341 Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-announces-publication-clinical Data published online in The Journal of Clinical Pharmacology SANTA MONICA, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic Wed, 03 Apr 2019 08:00:00 -0400 Opiant Pharmaceuticals, Inc. News Releases 8326 Opiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-announces-award-second-tranche SANTA MONICA, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, has been awarded the second tranche of $3.0 million from the total grant of approximately $7.4 Mon, 01 Apr 2019 08:00:00 -0400 Opiant Pharmaceuticals, Inc. News Releases 8321 Opiant Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-present-18th-annual-needham-healthcare SANTA MONICA, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that Roger Crystal , M.D., Opiant’s Chief Executive Officer, will provide a Thu, 28 Mar 2019 08:00:00 -0400 Opiant Pharmaceuticals, Inc. News Releases 8311 Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-inc-reports-fourth-quarter-and-full-year Addiction and Drug Overdose Pipeline Supported by Strong Cash Position; Expected to be in Range of $17M-$20M at End of 2019 SANTA MONICA, Calif. , March 21, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for Thu, 21 Mar 2019 16:05:00 -0400 Opiant Pharmaceuticals, Inc. News Releases 8291 Opiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21 https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-report-fiscal-2018-financial-results-and SANTA MONICA, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the year ended December 31, 2018 Mon, 18 Mar 2019 16:05:00 -0400 Opiant Pharmaceuticals, Inc. News Releases 8281 Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-announces-top-line-results-phase-2 -Study did not meet primary endpoint- -Company discontinuing development of OPNT001 for treatment of Bulimia Nervosa- -Focus remains on advancing lead product candidate, OPNT003, for treatment of opioid overdose, and other promising addiction and drug overdose-related product candidates- SANTA Thu, 21 Feb 2019 16:05:00 -0500 Opiant Pharmaceuticals, Inc. News Releases 8251 Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-licenses-novel-cb-1-receptor-antagonist Opiant Intends to Initiate Development Efforts in 2019 SANTA MONICA, Calif. , Dec. 26, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has entered into an Wed, 26 Dec 2018 08:00:00 -0500 Opiant Pharmaceuticals, Inc. News Releases 8196